Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 4/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.59 |
| ▸ | HTR1D | P28221 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | ATP4A | P20648 | 2/20 | 0.49 |
| ▸ | ATP4B | P51164 | 2/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293240 | 0.90 | TRPM8 (0.60) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL27725148 | 0.85 | TRPM8 (0.53) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL9772869 | 0.82 | TRPM8 (0.68) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL2004881 | 0.80 | TRPM8 (0.64) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL5808051 | 0.79 | TRPM8 (0.59) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL14174678 | 0.78 | TRPM8 (0.72) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL20115806 | 0.78 | ESR1 (0.59) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL12614535 | 0.77 | TRPM8 (0.61) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL2007192 | 0.77 | TRPM8 (0.72) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL27664101 | 0.77 | IMPDH2 (0.58) | TRPM8KDM4EMAPTLTA4HPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208505-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7087635-B2 | 3-substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1444224-B1 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | LILLY CO ELI (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | SALL DANIEL J (US) | 2005-07-21 | — | — | US | disclosed |
| US-6911463-B2 | 3-substituted oxindole β-3 agonists | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050080110-A1 | Beta 3 adrenergic agonists | SALL DANIEL JON (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | SALL DANIEL JON (US) | 2004-12-02 | — | — | US | disclosed |
| EP-1444224-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1421078-A1 | BETA-3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016276-A2 | 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-4217357-A | Inhibition of thromboxane synthetase with 3-(imidazol-1-ylalkyl)indoles | PFIZER INC. (US) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242668-A1 | 3-substituted oxindole beta-3 agonists | ADRB3, ADRB2, ADRB1 | TRPM8 1464/4885KDM4E 3972/4885MAPT 3614/4885 |
| US-20050159473-A1 | 3-Substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRB1 | TRPM8 1455/4885KDM4E 3960/4885MAPT 3541/4885 |
| US-20050080110-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | TRPM8 1769/4885KDM4E 3778/4885MAPT 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.